top of page

press releases

Nov 20

Glox Therapeutics Awarded £1M PACE Grant to Accelerate Development of Precision Antibiotics Against Antimicrobial-resistant Pathogens

Novel therapeutics to address unmet clinical need for pneumonias caused by drug-resistant Escherichia coli and Klebsiella pneumoniae PACE...

Nov 14, 2023

Glox Therapeutics Secures £4.3M Seed Funding to Develop Precision Antimicrobials

...Targeting Drug-resistant Bacteria Investment to accelerate development of a novel class of targeted high-potency bacteriocins against...

bottom of page